Relay Therapeutics reports 88% ORR at RP2D for RLY-4008 in FGFR2 fusion CCA

Relay Therapeutics, Inc.

At RP2D (70 mg QD), ORR 88% (15/17), confirmed ORR 82.4% (14/17), disease control rate 100%.
All-dose ORR 63.2% (24/38), confirmed ORR 57.9% (22/38), DCR 94.7%.
68% of patients remain on treatment; median follow-up 6 months (range <0.1-18.5).
No grade 4/5 treatment-related AEs; most common low-grade stomatitis (48%) and PPE (46%).
Abstract selected for oral presentation at ESMO Congress 2022 on Sept 11.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.